Reprint

Enhancing Mesenchymal Stem Cells (MSCs) for Therapeutic Purposes

Edited by
August 2022
204 pages
  • ISBN978-3-0365-4996-5 (Hardback)
  • ISBN978-3-0365-4995-8 (PDF)

This book is a reprint of the Special Issue Enhancing Mesenchymal Stem Cells (MSCs) for Therapeutic Purposes that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

The regenerative and immunomodulatory properties of mesenchymal stem cells (MSCs) have made these cells the focus of multiple pre-clinical studies and clinical trials. While the results from these clinical studies have established that MSCs are safe, the efficacy of these cells is not as well-established. In this regard, there have been increased efforts towards generating potentiated/activated MSCs with enhanced therapeutic efficacy. Research on the mechanisms for enhancing MSC potency and efficacy is an area of active study with great potential for translation into clinical settings. The purpose of this book is to bring together recent research from a broad range of topics relating to potentiation strategies for enhancing MSC therapeutic efficacy, including growth factor pre-conditioning, hypoxia, and 3D culture. The research compiled in this book increases the basic understanding of MSC culture techniques and describes some MSC preparations for potential novel therapeutic applications. 

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
cell therapy; immunomodulation; polyunsaturated fatty acid; CD206; phagocytosis; mesenchymal stem cells; Vadadustat; AKB-6548; preconditioning; priming; immunomodulation; secretome; chemotaxis; Wharton’s jelly mesenchymal stem cells; umbilical cord; oxygen conditions; secretory profile; neuroprotection; mesenchymal stem cells; mesenchymal stromal cells; 3D culture; neurospheres; spheroids; pluripotency; neural; quiescence; mesenchymal stromal cells; mesothelioma; malignant pleural mesothelioma (MPM); cell therapy; liver cirrhosis; placenta-derived mesenchymal stem cells; WKYMVm; combination therapy; iPSC-derived MSCs; iMSC secretome; pre-conditioning; angiogenesis; IFN-γ; hypoxia; potentiation of iMSC efficacy; nanofiber-hydrogel composite; spinal cord injury; inflammation; macrophages; secondary injury; astrocytes; axon growth; adipose tissue-derived stem cells (ASCs); autophagy; rapamycin; 3-methyladenine; immunosuppression; inflammation; mesenchymal stem cells; preconditioning; exosome; engineered cardiac patches; adipose-derived stem cell; paracrine potential; osteogenic differentiation; hepatocyte growth factor; fibroblast growth factor 2